Ανακοίνωση στο συνέδριο της ASTRO 2009 (American Society Therapeutic Radiology Oncology) στο Chicago, USA.
3-D VOLUMETRIC EVALUATION
OF RESPONSE IN 117 METASTATIC BRAIN MELANOMAS TREATED WITH BEAM-SHAPE
C. BOSKOS(1,2), A. GORGULHO(1), Ch. VALERY(3), M.A. DE PAIVA(1), M.T. SELCH(1), N. AGAZARYAN(1), G. BOISSERIE (3), Α. DE SALLES(1).
(1) UCLA, Radiosurgery Department, Los Angeles, California, USA
(2) 251 General Hospital of Airforce, Oncology Department, Athens, GREECE.
(3) Hôpital Pitié-Salpêtrière, Radiosurgery Department, Paris, FRANCE
Introduction: We report retrospectively the response of melanoma brain metastases treated with stereotactic radiosurgery (SRS) in UCLA Radiosurgery Department, evaluating the volumetric changes from the day of treatment.
Patients and methods: We evaluate 117 melanoma brain metastases in 39 patients (28 male, 11 female) treated with SRS. We use for SRS treatment a Novalis® 6 MV, with micro multileaf collimator M3® and software iPlan3®. The volumetric study of these patients was based on MRI images before and after SRS. Patients are selected with minimum follow up of 5 months and at least 2 MRI in this interval. Median follow up was 9.16 months (5.1 – 41.7). We induce the term of “speed of shrinkage” and “speed of growth” as the ratio between percentage of shrinkage or growth respectively and the interval. “Volumetric response” defined as decrease of the volume (shrinkage).
Median prescribed peripheral dose was 18Gy (range: 10-25) to the 90% prescription isodose line. Median age was 52 years (range: 27-77), median grade of Karnofsky index was 90 (range: 60-100) and mean volume 2.25 cm³ (range:0.03-32.23). Overestimated increased contrast enhanced volume was found in 6 hemorrhagic metastases which was excluded from the study
Results: Volumetric response reported in 95.3% of metastases with a mean delay to response 3.13 months (median 3.25). A subgroup of initially responding metastases (13.9%) finally relapsed with a mean delay of 7 months (median 6.69).
According to Kaplan-Meier analyses, actuarial LC for 6-month, 1-year and 2-years was 91.6%, 82%, 77.6% respectively.
For “LC group” median percentage of shrinkage was 80% (mean: 71%) and median speed of shrinkage 8%/month (mean: 9%). For “Relapsed group” median percentage of growth was 205% (mean: 191%) and median speed of growth 28.7%/month (mean: 98).
Small initial volume and increased speed of shrinkage found to be favorable predictor factors for complete response.
Conclusions: According to the accurate volumetric evaluation of melanoma brain metastases, SRS found to be an efficient therapeutic approach, in terms of decreasing volume, with a median delay for response 3.13 months. Speed of shrinkage and initial tumor volume are favorable predicting factors for complete response.